These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 19415280)

  • 21. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 22. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
    Ouwerkerk J; Boers-Doets C
    Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful desensitization of a patient with cetuximab hypersensitivity: A case report.
    Solduzian M; Anvari S; Taghvaye Masoumi H; Shahi F; Jahangard-Rafsanjani Z
    J Oncol Pharm Pract; 2019 Oct; 25(7):1726-1730. PubMed ID: 30142983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.
    Power DG; Shah MA; Asmis TR; Garcia JJ; Kemeny NE
    Invest New Drugs; 2010 Jun; 28(3):353-60. PubMed ID: 19468688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.
    Song X; Long SR; Barber B; Kassed CA; Healey M; Jones C; Zhao Z
    Curr Clin Pharmacol; 2012 Feb; 7(1):56-65. PubMed ID: 22299770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
    Helbling D; Borner M
    Ann Oncol; 2007 May; 18(5):963-4. PubMed ID: 17488734
    [No Abstract]   [Full Text] [Related]  

  • 28. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
    Lau SC; Chung V; Lim D; Shibata S
    J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
    Pettigrew M; Kavan P; Surprenant L; Lim HJ
    J Med Econ; 2016; 19(2):135-47. PubMed ID: 26442575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
    Saadeh CE; Lee HS
    Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
    Ariyama H; Kusaba H; Baba E
    Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
    Bauer KA; Hammerman S; Rapoport B; Lacouture ME
    Clin Colorectal Cancer; 2008 Sep; 7(5):309-14. PubMed ID: 18794062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
    Siena S; Glynne-Jones R; Adenis A; Thaler J; Preusser P; Aguilar EA; Aapro MS; Loos AH; Esser R; Wilke H
    Cancer; 2010 Apr; 116(7):1827-37. PubMed ID: 20143444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
    Bylsma LC; Dean R; Lowe K; Sangaré L; Alexander DD; Fryzek JP
    Cancer Med; 2019 Sep; 8(12):5800-5809. PubMed ID: 31376243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.